Literature DB >> 16836944

Probiotic use in irritable bowel syndrome.

Patrick Young1, Brooks D Cash.   

Abstract

Over the past several years, a number of studies have addressed the role of specific strains of bacteria, or combinations thereof, to alleviate certain symptoms of irritable bowel syndrome (IBS). More importantly, the precise factors that contribute to this therapeutic effect, such as modulations in cytokine levels and alterations in colonic motility, are being clarified. This review serves to summarize the evidence for the use of probiotics in the treatment of IBS and to place this information in clinical context. Potential future developments and areas of possible research are also discussed.

Entities:  

Mesh:

Year:  2006        PMID: 16836944     DOI: 10.1007/s11894-006-0053-1

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  43 in total

Review 1.  Probiotics used in human studies.

Authors:  David C Montrose; Martin H Floch
Journal:  J Clin Gastroenterol       Date:  2005-07       Impact factor: 3.062

2.  The impact of irritable bowel syndrome on health-related quality of life.

Authors:  I M Gralnek; R D Hays; A Kilbourne; B Naliboff; E A Mayer
Journal:  Gastroenterology       Date:  2000-09       Impact factor: 22.682

Review 3.  Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea.

Authors:  H Szajewska; J Mrukowicz
Journal:  Aliment Pharmacol Ther       Date:  2005-09-01       Impact factor: 8.171

4.  Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection.

Authors:  Antonio Tursi; Giovanni Brandimarte; Gian Marco Giorgetti; Maria Ester Modeo
Journal:  Med Sci Monit       Date:  2004-12

5.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

6.  Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.

Authors:  E Furrie; S Macfarlane; A Kennedy; J H Cummings; S V Walsh; D A O'neil; G T Macfarlane
Journal:  Gut       Date:  2005-02       Impact factor: 23.059

Review 7.  Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective.

Authors:  Surinder K Dhaliwal; Richard H Hunt
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-11       Impact factor: 2.566

8.  Treatment of bacterial vaginosis with lactobacilli.

Authors:  A Hallén; C Jarstrand; C Påhlson
Journal:  Sex Transm Dis       Date:  1992 May-Jun       Impact factor: 2.830

Review 9.  Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis.

Authors:  Aloysius L D'Souza; Chakravarthi Rajkumar; Jonathan Cooke; Christopher J Bulpitt
Journal:  BMJ       Date:  2002-06-08

10.  Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance.

Authors:  J McCarthy; L O'Mahony; L O'Callaghan; B Sheil; E E Vaughan; N Fitzsimons; J Fitzgibbon; G C O'Sullivan; B Kiely; J K Collins; F Shanahan
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more
  1 in total

1.  A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome.

Authors:  Lesley M Roberts; Deborah McCahon; Roger Holder; Sue Wilson; F D Richard Hobbs
Journal:  BMC Gastroenterol       Date:  2013-03-07       Impact factor: 3.067

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.